Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergmann, L.
Right arrow Articles by Hoelzer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergmann, L.
Right arrow Articles by Hoelzer, D.
Related Collections
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome

Lothar Bergmann, Cornelius Miething, Ulrich Maurer, Jürgen Brieger, Tunca Karakas, Eckhart Weidmann, and Dieter Hoelzer

From the Medical Clinic III, Hematology/Oncology, J.W. Goethe University, Frankfurt, Germany.

The tumor suppressor gene wt1 (Wilms' tumor gene) encodes for a zinc finger DNA-binding protein with predominantly transcription repressing properties. Because wt1 has been shown to be expressed in the vast majority of patients with acute myeloid leukemias (AML), we investigated the relevance of wt-1 mRNA expression regarding prognosis and possible prediction of relapse during follow-up. Totally bone marrow-derived blasts of 139 AML patients (129 newly diagnosed AML patients, 22 AML patients again in first relapse, and 10 AML patients analyzed primarily in first relapse) were studied for wt1 mRNA expression. Seventy-seven patients were analyzed for wt1 mRNA expression during follow-up. wt1-specific reverse transcription-polymerase chain reaction (RT-PCR) was performed and the amplification product was visually classified as not, weakly, moderately, or strongly amplified, as described previously. PCR products were quantitated by competitive PCR using a shortened homologous wt1 construct standard in representative cases. The expression of wt1 transcripts was correlated to age, French-American-British (FAB) subtype, phenotype, karyotype, and long-term survival. wt1 mRNA was detectable in 124 of 161 (77%) samples at diagnosis and in first relapse. wt1 expression was independent from age, antecedent myelodysplastic syndrome or FAB subtype, with the exception of a significant difference in M5 leukemias showing wt1 transcripts in only 40% (P = .0025). There was no correlation between the level of wt1 mRNA and response to treatment or the prognostic groups defined by the karyotype. Concerning long-term survival, patients with high levels of wt1 had a significantly worse overall survival (OS) than those with not detectable or low levels. The 3-year OS for all newly diagnosed AMLs was 13% and 38% (P = .038), respectively, and 12% and 43% (P = .014) for de novo AMLs. The difference was more distinct in patients less than 60 years of age. During follow-up, all patients achieving complete remission became wt1 negative. Reoccurrence of wt1 transcripts predicted relapse. The data indicate that high expression of wt1 mRNA is associated with a worse long-term prognosis.

Blood, Vol. 90 No. 3 (August 1), 1997: pp. 1217-1225
© 1997 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. W. King, S. Thomas, F. Corsi, L. Gao, R. Dina, R. Gillmore, K. Pigott, A. Kaisary, H. J. Stauss, and J. Waxman
IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer
Clin. Cancer Res., February 15, 2009; 15(4): 1145 - 1154.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet, M.-F. Belair, J.-p. Haymann, C. Legendre, and L. Baud
Sirolimus interacts with pathways essential for podocyte integrity
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 630 - 638.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
Clin. Cancer Res., November 15, 2008; 14(22): 7161 - 7166.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Paschka, G. Marcucci, A. S. Ruppert, S. P. Whitman, K. Mrozek, K. Maharry, C. Langer, C. D. Baldus, W. Zhao, B. L. Powell, et al.
Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol., October 1, 2008; 26(28): 4595 - 4602.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. P. Radich
Molecular Classification of Acute Myeloid Leukemia: Are We There Yet?
J. Clin. Oncol., October 1, 2008; 26(28): 4539 - 4541.
[Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. S. Makki, T. Heinzel, and C. Englert
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels
Nucleic Acids Res., July 1, 2008; 36(12): 4067 - 4078.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Rezvani, A. S. M. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, and A. J. Barrett
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Blood, January 1, 2008; 111(1): 236 - 242.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist, March 1, 2007; 12(3): 341 - 355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al.
Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches
Blood, December 15, 2006; 108(13): 4109 - 4117.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Heuser, G. Beutel, J. Krauter, K. Dohner, N. von Neuhoff, B. Schlegelberger, and A. Ganser
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
Blood, December 1, 2006; 108(12): 3898 - 3905.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. A. Simpson, E. A. Burwell, K. A. Thompson, S. Shahnaz, A. R. Chen, and D. M. Loeb
The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy
Blood, June 15, 2006; 107(12): 4695 - 4702.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. Lapillonne, A. Renneville, A. Auvrignon, C. Flamant, A. Blaise, C. Perot, J.-L. Lai, P. Ballerini, F. Mazingue, S. Fasola, et al.
High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia
J. Clin. Oncol., April 1, 2006; 24(10): 1507 - 1515.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Gillmore, S.-A. Xue, A. Holler, J. Kaeda, D. Hadjiminas, V. Healy, R. Dina, S. C. Parry, I. Bellantuono, Y. Ghani, et al.
Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer
Clin. Cancer Res., January 1, 2006; 12(1): 34 - 42.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt
Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia
Blood, August 1, 2005; 106(3): 938 - 945.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Renshaw, R. M. Orr, M. I. Walton, R. te Poele, R. D. Williams, E. V. Wancewicz, B. P. Monia, P. Workman, and K. Pritchard-Jones
Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival
Mol. Cancer Ther., November 1, 2004; 3(11): 1467 - 1484.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
PNAS, September 21, 2004; 101(38): 13885 - 13890.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Alberta, G. M. Springett, H. Rayburn, T. A. Natoli, J. Loring, J. A. Kreidberg, and D. Housman
Role of the WT1 tumor suppressor in murine hematopoiesis
Blood, April 1, 2003; 101(7): 2570 - 2574.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S.-i. Fujii, K. Shimizu, F. Koji, and F. Kawano
Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential
J. Leukoc. Biol., January 1, 2003; 73(1): 82 - 90.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
H. E. Heslop, F. K. Stevenson, and J. J. Molldrem
Immunotherapy of Hematologic Malignancy
Hematology, January 1, 2003; 2003(1): 331 - 349.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. A. Ghanem, T. H. Van der Kwast, J. C. Den Hollander, M. K. Sudaryo, M. H. A. Oomen, M. A. Noordzij, M. M. Van den Heuvel, S. M. Nassef, R. M. Nijman, and G. J. Van Steenbrugge
Expression and Prognostic Value of Wilms' Tumor 1 and Early Growth Response 1 Proteins in Nephroblastoma
Clin. Cancer Res., November 1, 2000; 6(11): 4265 - 4271.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Gaiger, V. Reese, M. L. Disis, and M. A. Cheever
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
Blood, August 15, 2000; 96(4): 1480 - 1489.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Ohminami, M. Yasukawa, and S. Fujita
HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
Blood, January 1, 2000; 95(1): 286 - 293.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
C. McCoy, S. B. McGee, and M. M. Cornwell
The Wilms' Tumor Suppressor, WT1, Inhibits 12-O-Tetradecanoylphorbol-13-acetate Activation of the Multidrug Resistance-1 Promoter
Cell Growth Differ., June 1, 1999; 10(6): 377 - 386.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
U. Maurer, F. Jehan, C. Englert, G. Hubinger, E. Weidmann, H. F. DeLuca, and L. Bergmann
The Wilms' Tumor Gene Product (WT1) Modulates the Response to 1,25-Dihydroxyvitamin D3 by Induction of the Vitamin D Receptor
J. Biol. Chem., February 2, 2001; 276(6): 3727 - 3732.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020